| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000025279 |
| Receipt No. | R000028241 |
| Scientific Title | The short-Term effect of a grain-derived processed food product ingestion on visceral fat area : a randomized controlled trial. |
| Date of disclosure of the study information | 2017/01/10 |
| Last modified on | 2019/07/30 (Ver. 7) |
| Basic information | ||
| Public title | The short-Term effect of a grain-derived processed food product ingestion on visceral fat area : a randomized controlled trial. | |
| Acronym | The short-Term effect of a grain-derived processed food product ingestion on visceral fat area : a randomized controlled trial. | |
| Scientific Title | The short-Term effect of a grain-derived processed food product ingestion on visceral fat area : a randomized controlled trial. | |
| Scientific Title:Acronym | The short-Term effect of a grain-derived processed food product ingestion on visceral fat area : a randomized controlled trial. | |
| Region |
|
|
| Condition | ||
| Condition | healthy humans | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate the effect of grain- derived processed product on visceral fat area |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | visceral fat area
4-wk repeated consumption |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Single blind -investigator(s) and assessor(s) are blinded |
| Control | No treatment |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | control
*body weight measurement every day at home *visceral fat area measurement every 2-wk. |
|
| Interventions/Control_2 | active: product code; S-001
*4-wk repeated consumption *body weight measurement every day at home *visceral fat area measurement every 2-wk |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1, 23<=BMI<30
2, 20<=Age<65 of healthy men and women 3, provided written informed consent from subjects |
|||
| Key exclusion criteria | 1, can't attend all of test SCR, 0,2 and 4-wk
2, liver, kidney and heart disease, or disorder of respiration endocrine, metabolism, nervous system consciousness, or diabetes, or other diseases 3, parson deviation from reference value of clinical trial, and are diagnosed with doctor 4, surgery or therapy within 2 months before the trial 5, medicine user for hyperglycaemia, lipidemia, or hypertension 6, user of supplements or foods with health claim 7, unpleasant feeling during blood drawing 8, donated 200mL or more blood within l month before the trial 9, skin disease, metal allergy and implanted pacemaker 10, changes in weight of 3kg or more within 3 month before the study 11, shift worker 12, business trip and travel planned for 5 consecutive days or more 13, allergies against any constituents in the test diet 14, heavy user of alcohol (800mL<=ingestion beer) 15, other clinical study or who intended to participate in one during the study period 16, can't write the dietary record, life record and body weight record 17, disagree with explanation for study 18, judged to be inappropriate as subject by physician in charge |
|||
| Target sample size | 20 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Higashi sinjyuku clinic | ||||||
| Division name | Director | ||||||
| Zip code | 169-0072 | ||||||
| Address | 1-11-3 Okubo Shinjuku-ku Tokyo | ||||||
| TEL | 03-6233-8581 | ||||||
| d-kameda@mediffom.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | New drag Research Center, Inc | ||||||
| Division name | Clinical Research Development | ||||||
| Zip code | 105-0001 | ||||||
| Address | 2-7-5 Toranomon Minato-ku Tokyo | ||||||
| TEL | 03-5510-6908 | ||||||
| Homepage URL | |||||||
| j-fujii@ndrcenter.co.jp | |||||||
| Sponsor | |
| Institute | Higashi sinjyuku clinic |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kao corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Miyawaki orthopedics clinic IRB |
| Address | 3-1-6 Ariake-cho, Eniwa city, Hokkaido |
| Tel | 0123-33-4026 |
| d-kameda@mediffom.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | Unpublished due to the protocol including the intellectual property rights |
| Publication of results | Unpublished |
| Result | |||||||
| URL related to results and publications | works in progress | ||||||
| Number of participants that the trial has enrolled | 44 | ||||||
| Results | There was a significant difference in primary outcome |
||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results | |||||||
| Baseline Characteristics | healthy human |
||||||
| Participant flow | 43 participants completed and 40 subjects were incorporated into the analyses |
||||||
| Adverse events | No adverse effect related to the test diets reported |
||||||
| Outcome measures | visceral fat area |
||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028241 |